Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
exoASO-STAT6 in Advanced HCC and Liver Metastases
NCT05375604Phase 1Terminated
- Sponsor
- Codiak BioSciences
- Start
- Jun 2022
- Primary completion
- May 2023
- Modality
- Lipid-based Nanoparticles, Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CDK-004 in hepatocellular carcinoma (HCC), gastric cancer (GC) and colorectal cancer (CRC), sponsored by Codiak BioSciences. Primary endpoint: Safety and Tolerability up to 2 years. Started Jun 2022; status: terminated.
02
Drugs
CDK-004
03
Conditions
hepatocellular carcinoma (HCC)gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05375604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375604.